(Q43038711)

12 November 2017

title

Hepatitis C virus seropositivity at the time of renal transplantation in the United States: associated factors and patient survival (English)

1 reference

12 November 2017

1 reference

1 reference

Batty DS Jr

1

1 reference

12 November 2017

Swanson SJ

2

1 reference

12 November 2017

Kirk AD

3

1 reference

12 November 2017

Ko CW

4

1 reference

12 November 2017

Agodoa LY

5

1 reference

12 November 2017

Abbott KC

6

1 reference

12 November 2017

language of work or name

English

0 references

publication date

1 July 2001

1 reference

American Journal of Transplantation

12 November 2017

published in

1 reference

12 November 2017

volume

1

1 reference

12 November 2017

issue

2

1 reference

12 November 2017

page(s)

179-184

1 reference

Hepatitis C virus infection in renal transplant recipients: epidemiology, clinical impact, serological confirmation and viral replication

12 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2001.10213.X

Impaired kidney transplant survival in patients with antibodies to hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2001.10213.X

Mortality caused by sepsis in patients with end-stage renal disease compared with the general population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2001.10213.X

Pathogenesis, natural history, treatment, and prevention of hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2001.10213.X

The natural history of hepatitis C virus infection: host, viral, and environmental factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2001.10213.X

Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2001.10213.X

Cirrhotic glomerulonephritis: incidence, morphology, clinical features, and pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2001.10213.X

Pretransplantation alpha-interferon therapy and the effect of hepatitis C virus infection on kidney allograft recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2001.10213.X

Histologic outcome of hepatitis C virus infection in renal transplant recipients and the effect of pretransplantation interferon treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2001.10213.X

Effect of interferon-alpha treatment in hemodialysis patients and renal transplant recipients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2001.10213.X

Efficacy and tolerance of interferon-alpha(2b) in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2001.10213.X

Hepatitis C in organ transplantation: its significance and influence on transplantation policies

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2001.10213.X

7 January 2021

Chronic hepatitis in kidney allograft recipients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2001.10213.X

7 January 2021

Prevalence of antibodies to hepatitis C in dialysis patients and transplant recipients with possible routes of transmission

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2001.10213.X

7 January 2021

Hepatitis C in renal transplant recipients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2001.10213.X

7 January 2021

The impact of renal transplantation on survival in hepatitis C-positive end-stage renal disease patients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2001.10213.X

7 January 2021

Risk of death among chronic dialysis patients infected with hepatitis C virus

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2001.10213.X

7 January 2021

Impact of hepatitis B and C virus on kidney transplantation outcome

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2001.10213.X

7 January 2021

Effects of hepatitis C infection and renal transplantation on survival in end-stage renal disease. The New England Organ Bank Hepatitis C Study Group

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2001.10213.X

7 January 2021

Demographic determinants of hepatitis C virus seroprevalence among blood donors

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2001.10213.X

7 January 2021

Donor hepatitis C virus status does not adversely affect short-term outcomes in HCV+ recipients in renal transplantation

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2001.10213.X

7 January 2021

Retrospective study on the impact of hepatitis C virus infection on kidney transplant patients over 20 years

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2001.10213.X

7 January 2021

Interferon-alpha in chronic hepatitis C infection in dialysis patients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-6143.2001.10213.X

7 January 2021

10.1034/J.1600-6143.2001.10213.X

Identifiers

DOI

1 reference

12 November 2017

1 reference